-transparent.png){kind=logo}
It has been suggested that PAF-acether may be an important mediator in asthma and a PAF antagonist may therefore have a potentially important role. PAF-acether has been shown to induce a dual inflammatory response in the skin of man and we investigated the effect of BN 52063, a PAF antagonist, on this response. At a dose of 80 mg, BN 52063 orally inhibited the inflammatory response to a sub-cutaneous injection of PAF-acether 400 ng. A late cutaneous response was not observed in any of the subjects. BN 52063 was also demonstrated to be well tolerated at doses of 20, 40, 80 and 120 mg with no significant side effects.
Related Publications
P Guinot, and
P Braquet, and
J Duchier, and
A Cournot
August 1986,
Pharmacological research communications,
P Guinot, and
P Braquet, and
J Duchier, and
A Cournot
April 1986,
European journal of pharmacology,
P Guinot, and
P Braquet, and
J Duchier, and
A Cournot
October 1985,
Biochemical and biophysical research communications,
P Guinot, and
P Braquet, and
J Duchier, and
A Cournot
February 1987,
Thrombosis research,
P Guinot, and
P Braquet, and
J Duchier, and
A Cournot
January 1992,
Lens and eye toxicity research,
P Guinot, and
P Braquet, and
J Duchier, and
A Cournot
October 1985,
Immunopharmacology,
P Guinot, and
P Braquet, and
J Duchier, and
A Cournot
January 1986,
Agents and actions,
P Guinot, and
P Braquet, and
J Duchier, and
A Cournot
January 1996,
Advances in experimental medicine and biology,
P Guinot, and
P Braquet, and
J Duchier, and
A Cournot
March 1987,
European journal of pharmacology,
P Guinot, and
P Braquet, and
J Duchier, and
A Cournot
January 1986,
Agents and actions,
